Meeting
2013 Gastrointestinal Cancers Symposium
A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer.
Authors
Inkeun Park
Department of Oncology, Asan Medical Center, Unive
Inkeun Park , Min-Hee Ryu , Baek-Yeol Ryoo , Myoung Joo Kang , Changsuk Lee , Young Soo Park , Yoon-Koo Kang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01049620
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr86)
DOI
10.1200/jco.2013.31.4_suppl.86
Abstract #
86
Poster Bd #
B30
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer.
First Author: Jifang Gong
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC).
First Author: Ryan Sugarman
Poster
2014 Gastrointestinal Cancers Symposium
A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.
First Author: Jifang Gong
Poster
2013 Gastrointestinal Cancers Symposium
A phase I dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer.
First Author: Changhoon Yoo